Japan approves Eisai-Biogen Alzheimer’s drug



Eisai Co. Ltd. and Biogen Inc. announced on Monday that Japanese authorities approved Leqembi, also known as lecanemab, their jointly produced treatment for Alzheimer’s disease.

Japan became the …

About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento